Objective: Autoimmune lymphoproliferative syndrome (ALPS) with FAS mutation (ALPS-FAS) is a nonmalignant, noninfectious, lymphoproliferative disease with autoimmunity. Given the central role of natural regulatory T cells (nTregs) conclusion: An abnormal Treg phenotype is observed in circulating lymphocytes of ALPS patients. However, these Tregs displayed a normal suppressive function on T effector proliferation in vitro. This is suggesting that lymphoproliferation observed in ALPS patients does not result from Tregs functional defect or T effector cells insensitivity to Tregs suppression.
, Marie-Claude Stolzenberg 1, 2 , Olivier Pelle 1, 3 , Capucine Picard 2, 4, 5, 6 , Benedicte Neven 1, 2, 4 , Alain Fischer 2, 4, 7 , Aude Magerus-Chatinet 1, 2 and Frederic Rieux-Laucat 1, 2 Objective: Autoimmune lymphoproliferative syndrome (ALPS) with FAS mutation (ALPS-FAS) is a nonmalignant, noninfectious, lymphoproliferative disease with autoimmunity. Given the central role of natural regulatory T cells (nTregs) in the control of lymphoproliferation and autoimmunity, we assessed nTreg-suppressive function in 16 patients with ALPS-FAS.
results: The proportion of CD25 high CD127 low Tregs was lower in ALPS-FAS patients than in healthy controls. This subset was correlated with a reduced CD25 expression in CD3 + CD4 + T cells from ALPS patients and thus an abnormally low proportion of CD25 high FOXP3 + Helios + T cells. The ALPS patients also displayed a high proportion of naïve Treg (FOXP3 low CD45RA + ) and an unusual subpopulation (CD4 + CD127 low CD15s + CD45RA + ). Despite this abnormal phenotype, the CD25 high CD127 low Tregs' suppressive function was unaffected. Furthermore, conventional T cells from FAS-mutated patients showed normal levels of sensitivity to Treg suppression. (5) (6) (7) (8) . Immunosuppressive treatments, including steroids or lymphotoxic drugs, are usually efficient to control the disease. Importantly, hyperactivation of the mTOR pathway has been shown to promote the lymphoproliferation in ALPS-FAS patients (9) . This seminal study on ALPS pathophysiology prompted the clinicians to use mTOR-inhibitorbased treatments in ALPS patients, which showed very good efficacy (10) . Mutations in TNFRSF6 impair the formation of the death-inducing-signaling complex or the Fas/Fas ligand interaction (either by modifying Fas' structure or precluding its membrane expression) (11) . Thus, a defect in this pathway leads to the expansion of T and B lymphocytes including self-antigenspecific populations and thus autoimmunity as a consequence of cell death resistance. Indeed, a well-designed experiment, taking advantage of a loss-of-start mutation accompanied with somatic loss of heterozygosity, evidenced a disturbed B-lymphocytes selection in ALPS-FAS patients (12) . Moreover, the role of the B-cell subset in the pathophysiology is also underlined by the increased risk of lymphoma, mostly of B-cell origin (13) (14) (15) . However, there is no correlation between the magnitude of the apoptosis defect in vitro and the severity of the disease in vivo. Moreover, some FAS mutations may not be sufficient to trigger the disease, since asymptomatic carriers of germline FAS mutations have been described (i.e., partial clinical penetrance). The magnitude of the functional T cell defect is similar in asymptomatic carriers and symptomatic patients. Furthermore, ALPS is the only autoimmune syndrome in which a germline mutation on one TNFRSF6 allele (72%) and a somatic mutation on the other (0.5%) leads to disease onset; this explains the observed clinical differences between carriers of heterozygous germline mutations. This accumulation of genetic events provides the mutated cells with a selective advantage and is thus analogous to Knudson's two-hit hypothesis of carcinogenesis (16) . This finding shows that somatic mutations can lead to autoimmune disease and might explain the incomplete penetrance observed in familial autoimmunity. Lastly, this finding implies the existence of factors that modify the onset of ALPS.
Along with programmed cell death, self-tolerance is also achieved via active suppression of lymphocyte proliferation by regulatory T cells (Tregs). The latter are defined phenotypically by the expression of CD4, FOXP3, and CD25 (the IL-2 receptor α chain) and the absence of CD127 (the IL-7 receptor) (17) . Tregs have a key role in the prevention of autoimmunity and inflammation, as evidenced by the early-onset, severe autoimmune diseases caused by defects in Treg function or development (18, 19) . Indeed, mutations of the human FOXP3 gene (encoding the forkhead box P3 transcription factor) result in a fatal, systemic, autoimmune and inflammatory disease linked to the syndrome called immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX).
CD25 deficiency also results in severe autoimmunity and allergy and is phenotypically indistinguishable from IPEX (20 neg eTregs among PBMCs from ALPS patients (ALPS) are compared with the values for CTs (CONTROL). The error bars correspond to the mean ± SD for duplicates. The mean ± SD (range) percentage of eTregs was 1.36 ± 0.17% (0.81-2.39%) in CTs (n = 12) and 1.19 ± 0.3% (0.41-3.25%) in ALPS patients (n = 9). The mean ± SD (range) percentage of natural Tregs was 0.87 ± 0.12% (0.46-1.64%) in CTs (n = 12) and 4.9 ± 0.97% (1.83-10.90%) in ALPS patients (n = 9). Statistical analyses were performed using a non-parametric Mann-Whitney U-test (***p < 0.0001). ns: not significant. In panel A, the mean ± SD (range) percentage of naïve Treg was 14.7 ± 1.6% (2-38.3%) for CTs (n = 25) and 35.3 ± 4.5% (15-82%) for ALPS patients (n = 16). In panel B, the mean ± SD (range) percentage of naïve Tconvs was 56.5 ± 3.3% (10-88.8%) for CTs (n = 35) and 70 ± 3.3% (41-92.6%) for ALPS patients (n = 16). Statistical analyses were performed using a non-parametric Mann-Whitney U-test (***p < 0.0001; *p = 0.0205).
suggested that the expression of Helios (an Ikaros family transcription factor that enhances FOXP3 expression by binding to the FOXP3 promoter (23) and represses the IL-2 gene promoter (24)) can be used to discriminate between (i) nTregs that differentiate in the thymus and (ii) induced Tregs (iTregs) or effector Treg (eTregs) that differentiate in the peripheral tissues following exposure to antigen (25) . However, it has also been shown that the Helios + and Helios − nTregs have similar levels of suppressor activity and FOXP3 expression-suggesting that a lack of Helios expression is not a perfect marker of human iTregs (26) .
Regulatory T cells suppress not only autoimmune responses but also other aberrant or excessive immune responses to nonself-antigens. There is now a growing body of evidence to suggest that Tregs can control almost all physiological or pathological 
CD4
low subpopulations (a) shows the mean ± SD (range) proportion of proliferating naïve conventional effector T cell (Tconvs) from healthy controls (CTs) (CT Tconv), after carboxyfluorescein succinimidyl ester (CFSE) staining and incubation for 5 days with staphylococcal enterotoxin (SEE) and autologous control dendritic cells (DCs) (CT DC) [n = 6; 88.1 ± 12% (67.3-94.7%)] or autologous control monocytes (CT Mono) [n = 6; 10.6± 4% (6-16%)]. Statistical analyses were performed using a non-parametric T-test (***p < 0.001). (b) shows the mean ± SD (range) proportion of proliferating naïve Tconvs from CTs (CT Tconv) after staining with CFSE and incubation for 5 days in the presence of SEE (0.2 ng/ml) or OKT3 (5 µg/ml) with either DC or monocytes. NA = nonactivated cells. CT Tregs were added (or not) to give a Tconv:Treg ratio of 0 or 1. The error bars correspond to the mean ± SD for duplicates.
responses of the adaptive immune system. Furthermore, several mechanisms of Treg-mediated suppression have been proposed; these include the secretion of immunosuppressive cytokines (IL-10 and TGF-β) and the cell-cell-contact-dependent suppression, functional modification, and killing of antigen-presenting cells (APCs). Alternatively, the absorption of cytokines by Tregs may deprive responder T cells of cytokines and thus induce apoptosis (27) . The effectiveness of this suppression also depends on the sensitivity/resistance of Tconvs to the inhibitory effects of Tregs. We hypothesized that this key checkpoint for self-tolerance controls the lymphoproliferation and autoimmunity observed in ALPS-Fas. Hence, in order to check whether one or more functional defects in the Treg and/or Tconv populations might be involved in ALPS, we investigated the Tregs' phenotype and function in ALPS patients with a Fas defect.
PaTienTs anD MeThODs cell isolation
Purified PBMCs from adult CTs (French Blood Transfusion Service, Paris, France) and patients with ALPS were prepared by density gradient centrifugation on Lymphoprep (Abcyss SA). The donor age range was 21-64 years for CTs and 6-33 years for patients with ALPS. Tconvs, Tregs, and dendritic cells (DCs) were sorted using flow cytometry.
antibodies and reagents
Anti-CD14 conjugated to violet blue was purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). FITC-anti-CD4, PE Cy5-anti-CD11c, PE-anti-CD25, BV650-anti-CD25, APC-anti-CD45RA, BV711-anti-CD15s, PE-anti-CD45RA, PC5-anti-CD28, and PE anti-CTLA-4 were obtained from BD Biosciences (Mountain View, CA, USA). PE CY7 anti-CD127, BV421-anti CCR7, PE-anti-CD59, and BV510-anti-CD27 were purchased from Sony Biotechnology (San Jose, CA, USA); PE-FOXP3, APC-FOXP3, and eF450-Helios were supplied by eBiosciences (San Diego, CA, USA); PC5 anti-ICOS, APC-anti-PD1, BV421-anti-CD39, APC-anti-GITR, and BV421-anti LAG3 were purchased from Biolegend (San Diego, CA, USA); and staphylococcal enterotoxin E (SEE) was purchased from Toxin Technology Inc.; and CellTrace carboxyfluorescein succinimidyl ester (CFSE) was purchased from Molecular Probes (Eugene, OR, USA). The anti-CD3 (OKT3) used for some proliferation assays was purchased from Biolegend (San Diego, CA, USA).
Purification of T cells From PbMcs and co-culture With sorted Dcs
PBMCs were incubated for 30 min at 4°C with specific, labeled monoclonal antibodies, washed, and then sorted using an ARIA II cytometer (BD Biosciences). Naïve Tconvs were defined as CD4 
CD14
− dendritic cell (DC) subpopulation from three healthy controls (CTs). (a) shows the proportion of proliferating naïve Tconvs from health controls (CTs) or from ALPS patients (ALPS Tconvs) incubated with staphylococcal enterotoxin E (SEE) and DCs from CTs (CT DC). The mean ± SD (range) proportion of CT Tconvs activated by CT DCs was 70 ± 12% (51-85.6%) (n = 13) and the mean ± SD (range) proportion of ALPS Tconvs activated by CT DCs was 67.4 ± 15.3% (48.3-87%) (n = 9). (b) shows the proportion of proliferating naïve Tconvs from three CTs (CT1, CT2, and CT3) and staining with carboxyfluorescein succinimidyl ester (CFSE) and incubation for 5 days with SEE and either DCs from three different CTs (CT1, CT2, and CT3) or DCs from ALPS patients. (c) shows the results of the in vitro suppression assay using total Tregs isolated from three CTs (CT1, CT2, and CT3) with a Tconv:Treg ratio of 1:1 or 1:0.2 and CFSE-stained naïve Tconvs from three CTs (CT1, CT2, and CT3) or ALPS patients (ALPS Tconvs). The assays were performed with SEE and DCs from the three CTs (CT1, CT2, and CT3) incubated for 5 days. The results are expressed in percentage of proliferating naïve Tconvs. The error bars correspond to the mean ± SD for duplicates. The percentage inhibition of proliferation is indicated in italics. Statistical analyses were performed using a non-parametric Mann-Whitney U-test (ns: not significant).
A FOXP3 staining/permeabilizing buffer set (eBiosciences) was used for the intracellular staining of FOXP3, Helios, and CTLA-4.
Patients and ethical aspects
We studied a cohort of 16 patients (summarized in Table 1 ) with typical manifestations of ALPS (adenopathy, lymphadenopathy, anemia, thrombopenia, and splenomegaly). The patients carried various heterozygous germline TNFRSF6 mutations affecting the intracellular domain of the protein and were all registered in the French national primary immunodeficiency database (CEREDIH, Paris, France) (16) . As indicated in Table 1 resUlTs
Phenotypic characteristics of Tregs in alPs Patients
We studied 16 ALPS patients ( Table 1) . By studying the CD25 and CD127 surface markers, we observed abnormally low percentages of the CD25 high CD127
low Treg subsets in all tested ALPS-Fas patients, relative to CTs (Figure 1A) . We then measured the combined intracellular expression of the transcription factors FOXP3 and Helios in CD3 + CD4 + -gated T cells, in order to estimate the proportion of Tregs. Although this proportion varied from one patient to another, there was no significant overall difference between patients and CTs. However, when assessing CD25, CD45RA, and CD127 as additional surface markers for Tregs, we observed an abnormally low CD25 expression, an abnormally high CD45RA expression, and a normal CD127 expression in the ALPS-FAS patients ( Figure 1B) . The low CD25 expression was observed in both FOXP3
+ and Helios + populations ( Figures 1C,D) ; this is an important observation, since the CD25 is conventionally used as a Treg marker (notably in combination with FOXP3 staining). Furthermore, we observed an abnormally high proportion of naïve Tregs (FOXP3 low CD45RA
+ ) relative to eTregs (FOXP3 high CD45RA − ) in the ALPS patients ( Figure 1E ). This nTreg/eTreg imbalance was not correlated with age (Figure 2A) . Similarly, we observed a slightly but significantly elevated proportion of the CD45RA + subset among Figure 2B) . We also investigated the expression of the Treg markers on activated, terminally differentiated and most strongly suppressive FOXP3 high eTregs. The latter specifically express the CD15s marker (sialyl Lewis X) recently described in human blood by Miyara et al. (28) . We observed a slightly higher proportion of CD4 + CD127 low CD15s + cells ( Figure 3A ) in six out of six ALPS patients tested, relative to CTs. Again, we observed a low expression of the CD25 marker ( Figure 3B ) and an intermediate level of FOXP3 expression ( Figure 3B) . By contrast, the levels of Helios expression were very similar in ALPS patients and CTs ( Figure 3B) . We then analyzed the expression of the CD45RA and CD15s markers on the CD4 + CD3 + FOXP3 + population in P7 and P14 ( Figure 3C,  panel 1 ). The proportion of the CD3 + CD4 + CD15s + CD45RA neg subpopulation was slightly decreased as compared to controls ( Figure 3C, panel 2) . Additional markers have been studied on CD4 + CD127 low CD15s + cells. We observed increased CCR7 and PD1 staining in three ALPS patients as compared to healthy controls (CTs) ( Figure S1 in Supplementary Material). The other markers such as CTLA4 are not modified.
assessment of Tconv sensitivity and Treg Function in samples From alPs Patients
We next investigated the Tregs' suppressive function on T cell proliferation with regard to naïve CD4 + CD45RA
Tconvs. The Tregs were stimulated for 5 days with SEE or anti-CD3 antibody (OKT3) in the presence of CD11c + CD4 low APCs. As previously described (29), we found that DCs (i) were more efficient as APCs than monocytes ( Figure S2 in Supplementary Material) and (ii) sustained the proliferation of naïve Tconvs (Figure 4A) . Furthermore, stimulation with SEE was stronger than stimulator with OKT3 ( Figure 4B) . The proliferation of naïve Tconvs was of the same magnitude for ALPS patients and CTs ( Figure 5A) . Moreover, the naïve Tconvs from patients were stimulated to a similar extent by DCs from three independent CTs-thus emphasizing the assay's reproducibility ( Figure 5B) . Furthermore, we observed that the proliferation of Tconvs from these three independent CTs was inhibited to a similar extent, which thus ruled out donor-related variations ( Figure 5C) . Likewise, the proliferation of Tconvs from ALPS patients was fully inhibited by Tregs from three independent CTs ( Figure 5C ). Furthermore, Tregs from patients and CTs exhibited similar levels of suppressive activity under autologous and heterologous conditions (Figure 6) . Similarly, the CD4 + CD127 low CD25 + CD15s + Tregs isolated from two ALPS patients exhibited the same level of suppressive activity as Tregs from CTs (Figure 7) .
DiscUssiOn
The role of FOXP3 + Tregs is critical for controlling organ-specific autoimmunity, as demonstrated by the early onset of autoimmune enteropathy and endocrinopathy in IPEX patients and in mice harboring FOXP3 mutations. The extrinsic lymphocyte apoptosis mediated by the death receptor FAS also constitutes a tolerance checkpoint. Indeed, patients or mice harboring an FAS deficiency develop an early-onset lymphoproliferative disease with autoimmunity (essentially against platelets and red cells). However, these two key tolerance checkpoints are unable to compensate for each other, since (i) FAS-mediated apoptosis does not control the autoimmunity that develops in FOXP3-deficient patients and (ii) Tregs do not control the autoimmunity observed in FAS-deficient patients. One can assume that in ALPS, some FAS-deficient target cells (i.e., gut epithelial cells and Langerhans beta cells in the pancreas) are more resistant to destruction by autoreactive T cells. This hypothesis is supported by the less severe autoimmune symptoms observed in FAS-and Tregdeficient mice (30) . Moreover, Treg dysfunction might account for the active proliferation seen in ALPS-FAS patients, since impaired FAS-mediated cell death might not fully account for the generalized lymphoproliferation observed in patients and murine models. Hence, we decided to assess the Treg phenotype in ALPS-FAS patients. We systematically observed low expression of the IL-2Ra chain (CD25), which was correlated with low proportions of CD3
+ Treg subsets. This result is consistent with the recently described role of IL-2R signaling in FOXP3 expression (31 
CD45RA
+ cells also express CCR7 and CD27 argues against the possibility that these cells are TEMRAs. In addition, the normal suppressive function observed in vitro and the lack of clinical symptoms usually observed in Treg-deficient patients (i.e., autoimmune enteropathy and endocrinopathy) support the hypothesis whereby Treg functions, in particular inhibition of Tconvs proliferation, are unaffected in patients with FAS deficiency-despite the abnormal phenotype observed for circulating cells. However, Tregs from ALPS have been activated with control APCs (because insufficient numbers of ALPS-APCs retrieved upon cell sorting). We thus cannot exclude a putative in vivo defect of ALPS Tregs on ALPS-APCs regarding cytokine production (such as IL-10) or modification of some surface molecules on ALPS-APCs (such as CD86). Nevertheless, ALPS patients do not present with clinical features observed in "Tregopathies" (i.e., FOXP3 or CTLA-4 deficiencies) such as lymphocytic tissue infiltrations and organ-specific autoimmunity, in particular autoimmune enteropathy.
In conclusion, our present results show that abnormal proportions of Treg subsets are not necessarily pathogenic features in ALPS. Despite an apparently abnormal Treg phenotype in ALPS-FAS patients, a regulatory defect is unlikely to account for the active lymphoproliferation observed in this disease. Thus, it is still not clear why Tregs cannot control the lymphoproliferation of FAS-deficient T cells and thus cannot prevent autoimmune cytopenia in ALPS patients. Better knowledge of which T cells and/or which types of stimulation are most strongly controlled by the Treg-associated apoptosis pathway may help to identify more specific therapeutic targets in the future.
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The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00718/ full#supplementary-material. + CD4 + -gated T lymphocytes isolated from three healthy controls (CTs) (CT) or three ALPS patients (ALPS: P7, P8, and P15) were stained for CD25 and CD127 (a). Next, CD4
+ CD127 − CD25 + -gated T cell subpopulations were stained for CTLA4. In parallel, for two of these patients (ALPS: P7 and P15), CD3
+ CD4 + -gated T lymphocytes isolated were also stained for CD15s and CD127. Next, CD4
+ CD127 − CD15s + -gated T cell subpopulations were stained for CTLA-4 (b). The CD4 + CD127 − CD15s + -gated T cell subpopulations of three other patients were also stained for CCR7, GITR, ICOS, CD39, LAG3, CD59, PD1, CD27, and CD28 (c). The mean intensity of fluorescence was added for the control and the ALPS patients. Histograms are normalized to mode for panel (c). 
